XSHE300966
Market cap253mUSD
Dec 25, Last price
16.06CNY
1D
-3.14%
1Q
6.78%
IPO
-61.80%
Name
Hubei Goto Biopharm Co Ltd
Chart & Performance
P/E
80.48
P/S
3.27
EPS
0.20
Div Yield, %
0.33%
Shrs. gr., 5y
6.45%
Rev. gr., 5y
5.31%
Revenues
566m
-6.31%
Net income
23m
-42.78%
CFO
68m
Dividend
Jun 12, 20240.016 CNY/sh
Profile
Hubei Goto Biopharm Co.,Ltd. engages in the production and sale of steroid hormone API's and intermediates in China. It offers starting materials, such as 9a-hydroxy-4-androstenedione(9a-OHAD), bisnoralcohol(BA), sitolactone, 1.4-androstadienedione(ADD), and 4-androstenedione(4-AD); intermediates, including estrogens, progesterone, nonsteroids, other hormones, and corticosteroids; and other pharmaceutical raw materials. The company was founded in 2006 and is based in Yicheng, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 566,399 -6.31% | 604,571 2.32% | 590,885 26.23% | ||||
Cost of revenue | 509,327 | 531,482 | 496,099 | ||||
Unusual Expense (Income) | |||||||
NOPBT | 57,072 | 73,090 | 94,787 | ||||
NOPBT Margin | 10.08% | 12.09% | 16.04% | ||||
Operating Taxes | (2,174) | 8,051 | |||||
Tax Rate | 8.49% | ||||||
NOPAT | 59,246 | 73,090 | 86,735 | ||||
Net income | 23,005 -42.78% | 40,205 -48.67% | 78,331 46.99% | ||||
Dividends | (6,094) | (15,678) | |||||
Dividend yield | 0.23% | 0.50% | |||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | 110,093 | 328,849 | 154,876 | ||||
Long-term debt | 653,451 | 445,866 | 13,330 | ||||
Deferred revenue | 84,327 | 69,705 | 42,981 | ||||
Other long-term liabilities | 30 | 49 | |||||
Net debt | 533,334 | 288,217 | (56,179) | ||||
| Cash flow | |||||||
Cash from operating activities | 68,133 | 58,004 | |||||
CAPEX | (409,255) | ||||||
Cash from investing activities | (402,348) | ||||||
Cash from financing activities | 15,593 | 713,296 | 207,002 | ||||
FCF | (322,426) | (323,974) | 466 | ||||
| Balance | |||||||
Cash | 181,975 | 453,430 | 210,015 | ||||
Long term investments | 48,235 | 33,069 | 14,370 | ||||
Excess cash | 201,890 | 456,270 | 194,841 | ||||
Stockholders' equity | 614,690 | 572,034 | 419,309 | ||||
Invested Capital | 1,669,248 | 1,357,444 | 826,694 | ||||
ROIC | 3.91% | 6.69% | 11.48% | ||||
ROCE | 3.05% | 4.03% | 9.28% | ||||
| EV | |||||||
Common stock shares outstanding | 115,025 | 115,277 | 115,277 | ||||
Price | 22.97 -14.93% | 27.00 -34.18% | 41.02 | ||||
Market cap | 2,642,126 -15.11% | 3,112,479 -34.18% | 4,728,663 | ||||
EV | 3,246,486 | 3,453,766 | 4,693,846 | ||||
EBITDA | 88,109 | 100,321 | 118,145 | ||||
EV/EBITDA | 36.85 | 34.43 | 39.73 | ||||
Interest | 13,552 | 13,372 | 5,174 | ||||
Interest/NOPBT | 23.75% | 18.30% | 5.46% | ||||